Ocular Therapeutix, Inc. (OCUL)
OCUL moved a median of -0.18% 30 minutes after news, and +0.42% by the close. How OCUL actually reacts to news — the realized, point-in-time move the market made, measured across 420 labeled events over the last three years with zero look-ahead.
OCUL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.10% | 46% | 420 |
| 30-min | -0.18% | 45% | 420 |
| 60-min | +0.09% | 53% | 420 |
| to close | +0.42% | 54% | 417 |
| Middle 50% of OCUL reactions | -1.25% to +1.12% |
|---|---|
| Median reaction (30-min) | -0.18% |
| Measured reactions | 420 |
Half of all Ocular Therapeutix, Inc. news events land between -1.25% and +1.12% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OCUL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 14 | -1.88% | 29% | -0.80% |
| Analyst downgrades | 11 | -1.15% | 36% | -2.16% |
| Coverage initiations | 21 | -1.46% | 24% | -4.04% |
| Rating reiterations | 84 | -0.10% | 46% | -0.15% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how OCUL ranks against every other measured name →
That’s how OCUL usually reacts — get an email when it moves on news →Email me when OCUL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OCUL's baseline. Nothing else.
Recent OCUL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.13% | +0.67% | |
| Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences | Press release | GlobeNewswire | -0.39% | -4.46% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.79% | -1.48% | |
| Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD | Press release | GlobeNewswire | -0.37% | -5.65% | |
| Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences | Press release | GlobeNewswire | +1.44% | +1.44% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.90% | +0.00% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.33% | — | |
| Form 10-Q OCULAR THERAPEUTIX, INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.60% | +0.60% | |
| Form 8-K OCULAR THERAPEUTIX, INC For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -0.60% | +0.60% | |
| Form S-8 OCULAR THERAPEUTIX, INC | SEC filing · Form S-8 | SEC EDGAR | -0.60% | +0.60% | |
| Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | -0.60% | +0.60% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.09% | -2.95% | |
| Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences | Press release | GlobeNewswire | -0.56% | -4.44% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.10% | +2.90% | |
| Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026 | Press release | GlobeNewswire | -3.59% | +4.90% | |
| Form 8-K OCULAR THERAPEUTIX, INC For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | +0.56% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.39% | -7.09% | |
| Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026 | Press release | GlobeNewswire | +1.24% | +3.53% | |
| Ocular Therapeutix™ to Host Investor Day on June 17, 2026 | Press release | GlobeNewswire | -2.38% | -5.89% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.43% | -1.40% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.10% | -4.03% | |
| Form 10-Q OCULAR THERAPEUTIX, INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.25% | +3.96% | |
| Form 8-K OCULAR THERAPEUTIX, INC For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +5.25% | +3.96% | |
| Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | +5.25% | +3.96% | |
| Form ARS OCULAR THERAPEUTIX, INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.75% | +0.64% | |
| Form DEF 14A OCULAR THERAPEUTIX, INC For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | -0.75% | +0.64% | |
| Form DEFA14A OCULAR THERAPEUTIX, INC | SEC filing · Form DEFA14A | SEC EDGAR | -0.75% | +0.64% | |
| Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD | Press release | GlobeNewswire | -0.34% | +0.00% | |
| Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026 | Press release | GlobeNewswire | +1.36% | -2.81% | |
| Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences | Press release | GlobeNewswire | +1.18% | +0.32% | |
| Ocular Therapeutix™ to Host Investor Day on June 17, 2026 | Press release | GlobeNewswire | +1.47% | +1.26% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.46% | -1.57% | |
| Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD | Press release | GlobeNewswire | +0.40% | +1.49% | |
| Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April | Press release | GlobeNewswire | +0.35% | -4.03% | |
| Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.80% | -1.50% | |
| Form 8-K OCULAR THERAPEUTIX, INC For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -0.12% | +25.92% | |
| Ocular Therapeutix™ to Participate in March Investor Conferences | Press release | GlobeNewswire | +2.01% | +5.98% | |
| Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations | Press release | GlobeNewswire | +4.12% | +8.38% | |
| Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 | Press release | GlobeNewswire | +5.37% | +8.20% | |
| Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.54% | +0.00% | |
| Form 10-K OCULAR THERAPEUTIX, INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +6.09% | +0.68% | |
| Form 8-K OCULAR THERAPEUTIX, INC For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | +6.09% | +0.68% | |
| Form S-8 OCULAR THERAPEUTIX, INC | SEC filing · Form S-8 | SEC EDGAR | +6.09% | +0.68% | |
| Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | +6.09% | +0.68% | |
| Form 8-K OCULAR THERAPEUTIX, INC For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -7.06% | |
| Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.04% | +6.76% | |
| Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer | Press release | GlobeNewswire | -0.83% | +0.09% | |
| Form 8-K OCULAR THERAPEUTIX, INC For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +1.00% | -3.31% | |
| Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD | Press release | GlobeNewswire | +9.45% | +9.97% | |
| Form 8-K OCULAR THERAPEUTIX, INC For: Dec 05 | SEC filing · Form 8-K | SEC EDGAR | +9.45% | +9.97% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OCUL section they belong to.
Where else OCUL is measured.
OCUL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AMPLIPHI BIOSCIENCES CORP (APHB) | 422 | -0.98% | 32% |
| Henry Schein, Inc. (HSIC) | 422 | -0.08% | 44% |
| ASTERIAS BIOTHERAPEUTICS INC (AST) | 416 | -0.53% | 34% |
| BIOPHARMX CORP (BPMX) | 416 | -1.58% | 28% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ocular Therapeutix, Inc.'s median reaction calculated?
Every labeled OCUL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 420 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of OCUL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OCUL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.